logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Alibaba-W (09988.HK) spent 2.26 million U.S. dollars on August 12 to repurchase 152,200 shares.

date
14/08/2025
Wisdom Financial News APP News, Alibaba-W (09988.HK) announced that on August 12, 2025, the company spent $2.2602 million to repurchase 152,200 shares at a repurchase price of $14.76-15.00 per share.
Latest
3 m ago
59 stocks receive buy rating from securities firms, Guizhou Maotai's target increase reaches 83.09%
3 m ago
Medytox (02159.HK) shareholders will transfer their stocks from Futu Securities International (Hong Kong) to Wanhai Securities (Hong Kong) with a transfer-in market value of 60.09 million Hong Kong dollars.
6 m ago
CITIC Securities stated that the National Medical Security Administration has issued the "Announcement on the Preliminary Review of Drugs and Related Information in the Adjustment of the Drug Catalogs for National Basic Medical Insurance, Maternity Insurance, Work-related Injury Insurance, and the Innovation Drug Catalog for Commercial Insurance by 2025". We believe that the first appearance of the commercial insurance innovation drug catalog is of symbolic significance, which is conducive to the development of commercial insurance and the expansion of the payment end, and more beneficial to the construction of a multi-level medical security system and the innovation of the pharmaceutical industry in China. The introduction process of the basic medical insurance and commercial insurance innovation drug catalogs in this round is relatively fast, and the inclusion of drug varieties exceeds expectations, with a wide range of categories, which highlights the National Medical Security Administration's new definition of "innovation". Continuing our investment strategy viewpoint for the second half of 2025, embracing innovation-driven and internationalization + independent controllable + out-of-hospital marketing mode reform will be a relatively more certain layout direction in the second half of the year. Considering that in addition to overseas gains, the innovative drug sector has received strong domestic policy support, we believe that the era of truly innovative and internationalized pharmaceuticals will bring returns and are expected to drive the sector steadily upwards. We suggest laying out in the second half of the year around the three areas of "innovation-driven and internationalization + independent controllable + out-of-hospital marketing mode reform" in the horizontal dimension, especially in the innovative drug sector with the most beta effect.
6 m ago
CITIC Securities; "Dual Catalogue" makes its first appearance, entering a new stage in multi-level medical supplementary insurance system.
7 m ago
Longpan Technology (02465.HK) shareholders will transfer their shares from Hong Kong Stock Connect (Shanghai) to BNP Paribas in France, with a total market value of 75.95 million Hong Kong dollars.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.